Aortic Stenosis with Angiodysplasia (Heyde's Syndrome)
Aortic valve replacement—preferably transcatheter aortic valve replacement (TAVR)—is the definitive first-line treatment for severe symptomatic aortic stenosis with gastrointestinal bleeding from angiodysplasia (Heyde's syndrome), as it addresses the underlying pathophysiology and resolves both the cardiac disease and bleeding diathesis.
Understanding the Pathophysiology
Heyde's syndrome represents a triad of severe aortic stenosis, gastrointestinal bleeding from angiodysplasia, and acquired von Willebrand syndrome type 2A. The high shear stress across the stenotic valve causes proteolysis of large von Willebrand factor multimers, creating both a bleeding diathesis and promoting angiodysplasia formation 1, 2. This means treating the valve directly addresses the root cause of the bleeding.
Treatment Algorithm
Step 1: Confirm the Diagnosis
- Echocardiography to assess aortic stenosis severity
- Endoscopy (gastroscopy, colonoscopy, capsule endoscopy) to identify angiodysplasia
- von Willebrand factor assay if available (though not required for management decisions)
- Assess for anemia and transfusion requirements
Step 2: Proceed Directly to Aortic Valve Replacement
For severe symptomatic aortic stenosis with Heyde's syndrome, valve replacement should be performed without delay 1, 3. The evidence strongly supports this approach:
- TAVR is preferred over surgical aortic valve replacement (SAVR) in elderly patients with Heyde's syndrome, showing lower rates of life-threatening bleeding, fewer perioperative complications, and reduced transfusion requirements 1
- 79%-86% of patients experience no recurrence of GI bleeding after TAVR 1
- Resolution of angiodysplasia has been documented on follow-up endoscopy after TAVR 3
- The bleeding typically resolves within weeks to months as von Willebrand factor levels normalize
Step 3: Temporizing Endoscopic Measures (If Needed)
Endoscopic treatment with argon plasma coagulation can be used for acute bleeding control while preparing for valve replacement, not as definitive therapy 4, 2. This is important because:
- Angiodysplasia treatment alone has high recurrence rates due to persistent von Willebrand syndrome 1
- Multiple lesions are often present throughout the GI tract
- New lesions continue to form until the valve is replaced
Step 4: Post-TAVR Management
Following TAVR, standard dual antiplatelet therapy (DAPT) for 3-6 months is recommended per guidelines 5, 1. Despite antiplatelet therapy, bleeding control is typically achieved because the underlying coagulopathy resolves.
Critical Decision Points
When the Patient is Extremely Frail or Has Limited Life Expectancy
Even in octogenarians and nonagenarians, TAVR should be strongly considered given its lower procedural risk compared to SAVR 6. However, TAVR is not recommended if:
- Life expectancy is <1 year even with successful procedure
- Chance of "survival with benefit" is <25% at 2 years 5
In such cases where valve replacement is truly not feasible, conservative management includes:
- Repeated endoscopic ablation of accessible lesions
- Iron supplementation and transfusion support
- Acceptance of ongoing anemia with transfusion-dependent status 6, 7
Special Consideration: Moderate Aortic Stenosis
Current guidelines address only severe AS 8, 5. For moderate AS with Heyde's syndrome, the evidence is limited 7. In this scenario, conservative management with endoscopic treatment and transfusion support is reasonable, but if symptoms progress or bleeding becomes refractory, consider valve replacement even with moderate stenosis given the pathophysiologic link.
Common Pitfalls to Avoid
Do not pursue repeated endoscopic interventions as primary therapy when severe AS is present—this delays definitive treatment and subjects patients to recurrent bleeding and transfusions 1, 3
Do not defer valve replacement due to concerns about antiplatelet therapy post-TAVR—the resolution of von Willebrand syndrome outweighs the antiplatelet risk 1, 2
Do not miss the diagnosis in elderly patients with unexplained anemia and AS—maintain high clinical suspicion and pursue capsule endoscopy if upper and lower endoscopy are negative 3, 9
Do not assume surgical risk is prohibitive—TAVR has transformed outcomes in high-risk elderly patients who previously would have been managed conservatively 2
The Evidence Base
The guideline framework for managing severe symptomatic AS supports intervention 8, 5, and recent research consistently demonstrates that valve replacement is curative for the bleeding diathesis in Heyde's syndrome 1, 4, 3, 2. The most compelling evidence comes from multiple 2025-2026 case series showing complete resolution of bleeding and angiodysplasia after TAVR 1, 3, with TAVR demonstrating superior safety profiles compared to SAVR in this elderly, often frail population.